Foghorn Therapeutics Financial Health
Financial Health criteria checks 3/6
Foghorn Therapeutics has a total shareholder equity of $-24.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $372.9M and $397.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$315.97m |
| Equity | -US$24.59m |
| Total liabilities | US$397.47m |
| Total assets | US$372.88m |
Recent financial health updates
Recent updates
Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Financial Position Analysis
Short Term Liabilities: FHTX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: FHTX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: FHTX is debt free.
Reducing Debt: FHTX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FHTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FHTX has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 51.1% each year.